Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,084 across all filing types
Latest filing 2024-08-15 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
2024年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2024 Semi-Annual Financial Report" (二〇二四年半年度财务报告) and contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity. The report covers the period ending June 30, 2024, which is a half-year period. The content includes comprehensive financial data and analysis, not just an announcement or summary. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-15 Chinese
关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by the company 西藏易明西雅医药科技股份有限公司. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. It references previous announcements and regulatory guidelines related to the share buyback. The document does not contain financial statements or detailed financial analysis but is a status update on the company's share repurchase activity. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2024-08-01 Chinese
2024年半年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2024 Half-Year Performance Forecast' and provides preliminary profit estimates for the period January 1, 2024 to June 30, 2024. It explicitly states that the data is preliminary, unaudited, and based on initial financial department calculations. It also mentions that the detailed financial data will be disclosed in the 2024 half-year report. The document is short (925 characters) and serves as an earnings forecast rather than a full interim or quarterly report containing actual financial statements or substantive financial data. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. H1 2024
2024-07-12 Chinese
关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by the company 西藏易明西雅医药科技股份有限公司. It details the number of shares repurchased, prices, total amount spent, and compliance with relevant regulations. The document does not contain full financial statements or comprehensive financial analysis but focuses on the update of the share buyback activity. This matches the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2024-07-02 Chinese
关于控股股东部分股份质押及解除质押的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged, released, and the related dates and parties involved. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledging activities, which fits the category of Transaction in Own Shares (POS) as it involves changes in the company's own shares held by a major shareholder. The document length is short and it is not a report or a certification, so it is not classified as a financial report or regulatory filing. Therefore, the appropriate classification is POS with high confidence.
2024-06-19 Chinese
关于大股东部分股份质押展期的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the extension of a pledge on shares held by a major shareholder. It details the number of shares pledged, the pledge period extension, and assurances about the shareholder's financial status and risk management. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory announcement about share pledge extension by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or financial disclosure. Therefore, the appropriate classification is MRQ with high confidence.
2024-06-13 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.